General Insights Hero 1920x480 (4:1)

Healthcare and Life Sciences Hot Topics: FDA Regulatory Considerations on Approvals for Artificial Intelligence

August 29, 2019
Washington, D.C. partners address FDA initiatives to modernize the marketing pathway for new products and the use of real world evidence for regulatory decision-making.
Washington, D.C. partners Ben Haas and Elizabeth Richards discuss the FDA’s efforts to modernize the regulatory pathway to marketing to account for artificial intelligence and machine learning in devices. In addition, they look at how FDA is viewing real world evidence and how it may be utilized for regulatory purposes.